Congresses

Titlesort descending Year
OPTIKA – a new high content drug combination dynamic assay / Hollow-fibre models 2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
PRELIMINARY STUDIES FOR THE ELUCIDATION OF THE MODE OF ACTION OF THE AVERMECTINS AS ANTI-TB AGENTS 2019
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity 2018
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells 2022
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU) 2022
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic 2022
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT 2018
Repurposing beta-lactams for buruli ulcer treatment 2018
Repurposing clinically approved cephalosporins for tuberculosis therapy 2017
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis 2019
Sesión II: Antimicrobianos (Moderador) 2018
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022

Pages